Remestemcel-L for the treatment of graft versus host disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Remestemcel-L, a third-party, off-the-shelf preparation of bone-marrow derived mesenchymal stromal cells (MSCs), has been developed for experimental use in acute graft-versus-host disease (aGvHD) and other immune-mediated conditions. Several preclinical and clinical studies have indeed suggested the potential of human mesenchymal stromal cells (MSCs) as an effective treatment for steroid-refractory aGvHD. However, an unambiguous demonstration of efficacy is still lacking. Areas covered: This review critically examines the biologic rationale supporting MSCs use in aGvHD and analyzes the results of published clinical trials in this setting, with a particular focus on the potential benefits and drawbacks of Remestemcel-L. For this purpose, a systematic literature search was performed in PubMed using the following keywords: 'mesenchymal stromal cells', 'mesenchymal progenitor cells', 'multipotent stromal cells', 'mesenchymal cells', 'MSC', 'Remestemcel-L', 'Prochymal', and 'graft-versus-host disease' or 'GvHD'. Expert commentary: Remestemcel-L represents a promising alternative to second-line immunosuppressive agents for the treatment of steroid-refractory aGvHD. Despite the safety and the favorable risk/benefit profile of this cell product, which has been demonstrated in several phase I-II studies, large and prospective randomized trials are required to confirm its efficacy in aGvHD and to define the optimal schedule of administration in terms of infusion timing, cell dose and pharmacological synergism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Human mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
Duijvestein, M., Vos, A. C. W., Roelofs, H., Wildenberg, M. E., Wendrich, B. B., Verspaget, H. W., Kooy-Winkelaar, E. M. C., Koning, F., Zwaginga, J. J., Fidder, H. H., et al. (2010) · Gut · doi:10.1136/gut.2010.215152 · Cited by 622 · cited 1×
“As an example, MSCs represented a feasible, safe, and beneficial therapy in refractory Crohn’s disease both when systemically infused for the control of luminal forms and when locally injected in perianal fistulizing lesions [90,91].”
BackgroundTarte, K., Gaillard, J., Lataillade, J.-J., Fouillard, L., Becker, M., Mossafa, H., Tchirkov, A., Rouard, H., Henry, C., Splingard, M., et al. (2010) · Blood · doi:10.1182/blood-2009-05-219907 · Cited by 430 · cited 1×
“Indeed, several groups observed karyotype abnormalities in cultured BM-MSCs from both humans and animals, but these cases merely seem related to the occurrence of senescence [66,67].”
BackgroundChinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301828 · Cited by 266 · cited 2×
“During the whole process, the cytokine milieu of aGvHD exerts a key role in MSCs activation and polarization towards an anti-inflammatory phenotype, characterized by enhanced secretion of soluble factors, including IDO, PGE2, TGF-?, and up-regulation of surface inhibitory molecules, such as PD-L1. an attractive clinic…”
BackgroundProckop, D. J. (2013) · Stem Cells · doi:10.1002/stem.1400 · Cited by 230
Cited by
Mesenchymal stem cell perspective: cell biology to clinical progress
Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A. I. (2019) · npj Regenerative Medicine · doi:10.1038/s41536-019-0083-6 · Cited by 2,008
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application
Caplan, H., Olson, S. D., Kumar, A., George, M., Prabhakara, K. S., Wenzel, P., Bedi, S., Toledano-Furman, N. E., Triolo, F., Kamhieh-Milz, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01645 · Cited by 306
Clarifying Stem-Cell Therapy’s Benefits and Risks
Marks, P. W., Witten, C. M., & Califf, R. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1613723 · Cited by 286
Cell Therapy: Types, Regulation, and Clinical Benefits
El-Kadiry, A. E.-H., Rafei, M., & Shammaa, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756029 · Cited by 256
Metadata
- Authors
- Locatelli, F., Algeri, M., Trevisan, V, & Bertaina, A.
- Venue
- Expert Review of Clinical Immunology
- Publisher
- Informa UK Limited
- Published
- 2016-07-29
- Volume
- 13
- Issue
- 1
- Pages
- 43-56
- ISSN
- 1744-666X (ISSN-L)
- 1744-8409
- OpenAlex
- W2465027035
- Cited by
- 41
- References
- 6
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remestemcel-L for the treatment of graft versus host disease. https://app.cochat.ai/papers/10.1080/1744666x.2016.1208086
- The paper
- Locatelli, F., Algeri, M., Trevisan, V, & Bertaina, A. (2017). Remestemcel-L for the treatment of graft versus host disease. Expert Review of Clinical Immunology. https://doi.org/10.1080/1744666x.2016.1208086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.